New approaches for mesothelioma: Biologics, vaccines, gene therapy, and other novel agents

This publication has 75 references indexed in Scilit:

• Combination raltitrexed (Tomudex®)–oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma
  European Journal Of Cancer, 2000
• Mutations of p53 gene and SV40 sequences in asbestos associated and non-asbestos-associated mesotheliomas.
  Journal of Clinical Pathology, 1999
• Evaluation of an E1E4-Deleted Adenovirus Expressing the Herpes Simplex Thymidine Kinase Suicide Gene in Cancer Gene Therapy
  Human Gene Therapy, 1999
• Higher doses of α-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma
  European Journal Of Cancer, 1997
• MOLECULAR PATHOBIOLOGY AND IMMUNOLOGY OF MALIGNANT MESOTHELIOMA
  The Journal of Pathology, 1996
• Interferon (IFN)-α and IFN-γ in combination with methotrexate
  Anti-Cancer Drugs, 1995
• Differential expression of platelet derived growth factor-β in malignant mesothelioma: a clue to future therapies?
  Surgical Oncology, 1993
• Asbestos fibres inhibit the in vitro activity of ymphokine-activated killer (LAK) cells from healthy individualsand patients with malignant mesothelioma
  Clinical and Experimental Immunology, 1991
• Capacity of tumor necrosis factor to augment lymphocyte-mediated tumor cell lysis of malignant mesothelioma
  Clinical Immunology and Immunopathology, 1991
• Immunotherapy of Metastases Enhances Subsequent Chemotherapy
  Science, 1982